NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free DSGN Stock Alerts $4.41 -0.09 (-2.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.37▼$4.5550-Day Range$2.48▼$4.7752-Week Range$1.94▼$8.31Volume121,302 shsAverage Volume331,017 shsMarket Capitalization$249.12 millionP/E RatioN/ADividend YieldN/APrice Target$6.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Design Therapeutics alerts: Email Address Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside49.7% Upside$6.60 Price TargetShort InterestBearish9.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.09Based on 4 Articles This WeekInsider TradingAcquiring Shares$99,750 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.02) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 starsMedical Sector503rd out of 918 stocksPharmaceutical Preparations Industry231st out of 423 stocks 3.1 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Design Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.06% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Design Therapeutics has recently increased by 25.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 3.4 News and Social Media Coverage News SentimentDesign Therapeutics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Design Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for DSGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.80% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Design Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Design Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesMay 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Design Therapeutics, Inc. (NASDAQ:DSGN) Lifted by AnalystMay 10, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewMay 10, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial ReviewMay 9, 2024 | americanbankingnews.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Hold" from AnalystsMay 9, 2024 | msn.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 8, 2024 | americanbankingnews.comDesign Therapeutics (NASDAQ:DSGN) Upgraded to Overweight at Piper SandlerMay 7, 2024 | msn.comPiper Sandler Upgrades Design Therapeutics (DSGN)May 7, 2024 | msn.comDesign Therapeutics climbs as Piper Sandler upgrades on pipelineMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Design Therapeutics’ Innovative Pipeline and Solid FinancialsMay 7, 2024 | globenewswire.comDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMarch 27, 2024 | finance.yahoo.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 26, 2024 | msn.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 21, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)March 21, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program UpdatesMarch 20, 2024 | stockhouse.comDesign Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | investorplace.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline ProgressMarch 19, 2024 | globenewswire.comDesign Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | investing.comDesign Therapeutics Inc (DSGN)March 18, 2024 | benzinga.comEarnings Preview For Design TherapeuticsMarch 15, 2024 | finance.yahoo.comDSGN Jul 2024 2.500 putMarch 15, 2024 | finance.yahoo.comDSGN Apr 2024 7.500 putMarch 12, 2024 | globenewswire.comDesign Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateFebruary 9, 2024 | benzinga.comSR ONE CAPITAL PARTNERS I, LP's Net WorthSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/18/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+49.7%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.79% Return on Assets-19.89% Debt Debt-to-Equity RatioN/A Current Ratio38.61 Quick Ratio38.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book0.92Miscellaneous Outstanding Shares56,490,000Free Float40,789,000Market Cap$249.12 million OptionableOptionable Beta1.83 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 54)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $638.46kDr. Sean Jeffries Ph.D. (Age 44)Chief Operating Officer Comp: $572.21kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Jae B. Kim FACC (Age 54)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsImmutepNASDAQ:IMMPAkebia TherapeuticsNASDAQ:AKBAAldeyra TherapeuticsNASDAQ:ALDXPyxis OncologyNASDAQ:PYXSOmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 47,098 shares on 5/16/2024Ownership: 0.889%Baker BROS. Advisors LPBought 162,120 shares on 5/15/2024Ownership: 2.942%Public Employees Retirement System of OhioSold 2,590 shares on 5/15/2024Ownership: 0.042%Price T Rowe Associates Inc. MDBought 11,147 shares on 5/15/2024Ownership: 0.020%Acadian Asset Management LLCBought 222,805 shares on 5/10/2024Ownership: 0.714%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions Should I buy or sell Design Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. What is Design Therapeutics' stock price target for 2024? 6 equities research analysts have issued 12-month target prices for Design Therapeutics' shares. Their DSGN share price targets range from $4.00 to $12.00. On average, they expect the company's stock price to reach $6.60 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. How have DSGN shares performed in 2024? Design Therapeutics' stock was trading at $2.65 at the beginning of 2024. Since then, DSGN shares have increased by 66.4% and is now trading at $4.41. View the best growth stocks for 2024 here. When is Design Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our DSGN earnings forecast. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) posted its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.11. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Design Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (2.94%), Vanguard Group Inc. (2.28%), BML Capital Management LLC (1.56%), Jacobs Levy Equity Management Inc. (0.89%), Acadian Asset Management LLC (0.71%) and Assenagon Asset Management S.A. (0.62%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, John P Schmid, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyProtect Your Bank Account Before It’s Too LateWeiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.